Actively Recruiting
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-04-06
400
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
CONDITIONS
Official Title
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with suspected or clearly diagnosed SSTR positive tumors
- Signed written consent
- Willing and able to cooperate with all projects in this study
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Any medical condition that may significantly interfere with study compliance in the opinion of the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Chao Yang, China, 100021
Actively Recruiting
Research Team
G
Gouzhu Hou, M.D.
CONTACT
X
Xin Cheng, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here